Optical spectroscopy and treatment planning software for photodynamic therapy of hollow cavities
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12616373-B2
Publication Date
2026-05-05
Expiration Date
Abstract
The present invention provides an optical probe system that allows for determination of optical properties at the wall of a hollow cavity and photosensitizer uptake at the time of photodynamic therapy (PDT). In one embodiment, this system provides for rigorous treatment planning to maximize efficacy and minimize risk to patients by optimizing the concentration of the scattering emulsion infused into the cavity and the delivered laser power.
Core Innovation
The invention provides a method for delivering, detecting, and analyzing diffuse optical reflectance and fluorescence in a target tissue using an optical probe system that includes at least one transmitting fiber, at least one receiving fiber, a light source, a spectrometer, and a controller. The probe is positioned at a surface of the target tissue so that fluorescence or reflectance measurements are enabled by selecting the at least one light source. A first spectra is detected with the light source enabled, and a second spectra is detected without the light source enabled to correct for dark background.
The controller corrects the first spectra for at least one of dark background, system throughput, and wavelength-dependent system response. The corrected spectra are analyzed to obtain optical property spectra for both absorption and scattering. The method includes a control spectra at the surface of the target tissue in the absence of delivering light and determining one or more optical properties of the target tissue based on the first spectra.
The method performs an initial simulation of light propagation in the target tissue at a set scattering emulsion concentration and optical power, and determines the scattering emulsion concentration at which minimum laser power is required to achieve a fluence rate target in 95% of the target tissue. The overall workflow integrates diffuse optical reflectance and fluorescence measurements with corrected optical-property extraction and simulation-driven selection of scattering emulsion concentration and laser power to meet a spatial fluence-rate target, followed by treating a subject using the determined scattering emulsion concentration and laser power.
Claims Coverage
The partial content includes two independent claims. Across these claims, the coverage centers on optical probe-based delivery and detection of diffuse reflectance and fluorescence spectra, spectra correction using controls and system-response factors, determination of optical properties, and simulation-based selection of scattering emulsion concentration and laser power to meet a fluence-rate target in 95% of the target tissue, followed by treating a subject.
Optical probe delivery and dual spectra detection with control
Providing an optical probe system comprising at least one transmitting fiber, at least one receiving fiber, at least one light source, a spectrometer, and a controller; positioning the proximal ends at a surface of a target tissue; enabling and selecting the at least one light source for fluorescence or reflectance measurements; detecting a first spectra with the at least one light source enabled; and detecting a second spectra without the at least one light source enabled to correct for dark background.
Spectra correction and extraction of absorption and scattering optical property spectra
Correcting the first spectra for at least one of dark background, system throughput, and wavelength-dependent system response; and analyzing the corrected first spectra by the controller to obtain optical property spectra for both absorption and scattering.
Simulation-based selection of scattering emulsion concentration and minimum laser power for a 95% fluence-rate target
Performing an initial simulation of light propagation at a set scattering emulsion concentration and optical power; determining the scattering emulsion concentration at which minimum laser power is required to achieve a fluence rate target in 95% of the target tissue; and treating a subject using the determined scattering emulsion concentration and laser power.
Control-based spectra correction without delivering light
Detecting a control spectra at the surface of the target tissue in the absence of delivering light; correcting the first spectra based in part on the control spectra for at least one of dark background, system throughput, and wavelength-dependent system response; and determining one or more optical properties of the target tissue based on the first spectra.
Simulation of light propagation and treating based on 95% fluence-rate targeting
Performing a simulation of light propagation in the target tissue at a set scattering emulsion concentration and optical power; determining a scattering emulsion at which a minimum laser power is required to achieve a fluence rate target in 95% of the target tissue; and treating a subject using the determined scattering emulsion concentration and laser power.
Across the two independent claims, coverage is directed to a spectra-based optical probe workflow, correction of measured spectra using dark-background/control and system-response factors, determination of optical properties including absorption and scattering spectra, and a simulation-driven selection of scattering emulsion concentration and laser power to achieve a fluence rate target in 95% of the target tissue, followed by treating a subject.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?